Non-Hodgkin Lymphoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD20 + | Non-Hodgkin Lymphoma | Rituximab | FDA |
| Sensitivity (+) | CD20 + | Non-Hodgkin Lymphoma | Cyclophosphamide, Prednisolone, Rituximab, Vincristine | FDA |
| Sensitivity (+) | CD20 + | Non-Hodgkin Lymphoma | Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine | FDA |
| Sensitivity (+) | CD20 + | Non-Hodgkin Lymphoma | Cyclophosphamide, Fludarabine, Mitoxantrone, Rituximab | FDA |
| Sensitivity (+) | CD20 + | Non-Hodgkin Lymphoma | Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine | FDA |
| Sensitivity (+) | CD20 + | Non-Hodgkin Lymphoma | Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine | FDA |
| Sensitivity (+) | CD20 + | Non-Hodgkin Lymphoma | Rituximab | HC |